

II. REMARKS

A. Status of the Claims

Claims 1-14 were originally filed. Claims 10-14 have been withdrawn as being directed to a non-elected invention. Therefore, claims 1-9 are currently under consideration.

B. Response to Restriction Requirement

In response to the Restriction Requirement imposed by the Examiner, Applicants herein elect, without traverse, the Group I invention, claims 1-9, drawn to a MUC1 chemiceric polypeptide comprising a MUC1-EC polypeptide and a human immunoglobulin Fc polypeptide or a human albumin polypeptide and a pharmaceutical composition comprising such. Claims 10-14 have been withdrawn as being directed to a non-elected invention.

Applicants further elect, without traverse, the following 10 MUC1-EC polypeptide sequences in response to the Restriction Requirement imposed by the Examiner:

SEQ ID NO: 1

SEQ ID NO: 3

SEQ ID NO: 5

SEQ ID NO: 9

SEQ ID NO: 11

SEQ ID NO: 15

SEQ ID NO: 17

SEQ ID NO: 19


SEQ ID NO: 25

SEQ ID NO: 27

Each of claims 1-9 reads on the elected sequences.

The Examiner is invited to contact the undersigned attorney at (512) 536-5639 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Monica A. De La Paz
Reg. No. 54,662
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201
(512) 536-4598 (fax)

Date: October 31, 2008